NRX Pharmaceuticals Inc (NRXP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NRX Pharmaceuticals Inc (NRXP) has a cash flow conversion efficiency ratio of 0.112x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.89 Million) by net assets ($-25.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NRX Pharmaceuticals Inc (NRXP) net asset quality to measure how much of total assets are equity-financed.
NRX Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how NRX Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of NRX Pharmaceuticals Inc to evaluate the quality of earnings relative to operating cash generation.
NRX Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NRX Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NOVONIX LTD SP.ADS/4
F:GC30
|
N/A |
|
Africa Energy Corp
V:AFE
|
-0.016x |
|
T7 Global Bhd
KLSE:7228
|
0.023x |
|
GBM Resources Limited
AU:GBM
|
-0.031x |
|
Li-S Energy Ltd
AU:LIS
|
-0.023x |
|
Quantum X Labs Inc.
NASDAQ:QXL
|
-0.028x |
|
Pearl Diver Credit Company Inc.
NYSE:PDCC
|
0.083x |
|
Thinkific Labs Inc
TO:THNC
|
-0.004x |
Annual Cash Flow Conversion Efficiency for NRX Pharmaceuticals Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of NRX Pharmaceuticals Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see NRXP company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-23.22 Million | $-10.64 Million | 0.458x | -75.19% |
| 2023-12-31 | $-11.73 Million | $-21.66 Million | 1.846x | +134.40% |
| 2022-12-31 | $7.41 Million | $-39.76 Million | -5.366x | -196.10% |
| 2021-12-31 | $20.81 Million | $-37.70 Million | -1.812x | -3601.91% |
| 2020-12-31 | $-43.77 Million | $-2.27 Million | 0.052x | +292.57% |
| 2019-12-31 | $29.50 Million | $-792.73K | -0.027x | -294.90% |
| 2018-12-31 | $69.54 Million | $-473.19K | -0.007x | -248.09% |
| 2017-12-31 | $69.47 Million | $-135.81K | -0.002x | -- |
About NRX Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in p… Read more